Eplerenone
- Generic Name
- Eplerenone
- Brand Names
- Inspra
- Drug Type
- Small Molecule
- Chemical Formula
- C24H30O6
- CAS Number
- 107724-20-9
- Unique Ingredient Identifier
- 6995V82D0B
- Background
Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the ef...
- Indication
For improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and clinical evidence of congestive heart failure after an acute myocardial infarction.
- Associated Conditions
- Hypertension, LVEF <40% Congestive heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class II)
- Associated Therapies
- -
Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Santhera Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT06649409
- Locations
- 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany
Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 100
- Registration Number
- NCT06168994
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
- Conditions
- Interventions
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT05593055
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Eplerenone Versus PDT: Comparative Study by OCTA
- Conditions
- Interventions
- First Posted Date
- 2021-11-02
- Last Posted Date
- 2021-11-02
- Lead Sponsor
- Federico II University
- Target Recruit Count
- 30
- Registration Number
- NCT05104138
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
- First Posted Date
- 2021-09-01
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05030545
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
MR Antagonist and LSD1
- Conditions
- Interventions
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT04840342
- Locations
- 🇺🇸
Brigham and Women's, Boston, Massachusetts, United States
Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity
- Conditions
- Interventions
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT04519164
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2021-01-08
- Lead Sponsor
- Wagner Macula & Retina Center
- Target Recruit Count
- 2
- Registration Number
- NCT04300881
- Locations
- 🇺🇸
Wagner Macula & Retina Center, Norfolk, Virginia, United States
A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart Failure
- First Posted Date
- 2019-06-13
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Bispebjerg Hospital
- Target Recruit Count
- 7200
- Registration Number
- NCT03984591
- Locations
- 🇩🇰
Bispebjerg Hospital, Copenhagen, Denmark
Pressure Assessment to Improve Outcomes After TAVR: a Registry
- Conditions
- Interventions
- First Posted Date
- 2019-04-22
- Last Posted Date
- 2020-05-28
- Target Recruit Count
- 12
- Registration Number
- NCT03923530
- Locations
- 🇺🇸
Malcom Randall VA Medical Center, Gainesville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.